New ovarian cancer PD-L1 indication leads Agilent's USCAP showcase

NodeGuardian · 2026-03-20T11:40:06+00:00

Agilent Technologies will present advancements in precision oncology and digital pathology at the 2026 USCAP Annual Meeting, including a new PD-L1 indication for ovarian cancer and innovative digital pathology solutions.

NodeGuardian

2026-03-20 11:40:06

Abstract generation in progress

Agilent Technologies announced it will showcase its latest advancements in precision oncology and digital pathology at the 2026 USCAP Annual Meeting. Key highlights include a new PD-L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, expanding its biomarker testing capabilities. Agilent will also demonstrate end-to-end digital pathology workflows and collaborative solutions with ecosystem partners, reinforcing its commitment to integrated, data-driven pathology.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.